The News Scroll 02 June 2020  Last Updated at 5:11 pm | Source: PTI

Lupin gets USFDA nod for generic product

Lupin gets USFDA nod for generic product
outlookindia.com
1970-01-01T05:30:00+0530
New Delhi, Jun 2 (PTI) Drug maker Lupin on Tuesday said it has received approval from the US health regulator to market Meloxicam capsules, used to treat osteoarthritis pain, in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) for meloxicam capsules in strength of 5 mg and 10 mg, Lupin Ltd said in a statement.

The Mumbai-based company''s product is the generic version of Zyla Life Sciences US, Inc''s Vivlodex capsules, it added.

"The product would be manufactured at company''s Aurangabad facility, and is expected to be launched shortly," the drug maker said.

Meloxicam capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain.

According to IQVIA MAT March 2020 data, Meloxicam capsules had annual sales of around USD 14 million in the US. PTI MSS HRS


Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI
Next Story : IndiGo flies into Rs 871 cr quarterly loss on higher expenses
Download the Outlook ​Magazines App. Six magazines, wherever you go! Play Store and App Store